Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ‐12420), a novel potassium‐competitive acid blocker, in healthy male subjects
Alimentary Pharmacology & Therapeutics2019Vol. 50(7), pp. 751–759
Citations Over TimeTop 10% of 2019 papers
Sungpil Han, Hee Youn Choi, Yo Han Kim, Ji Yeon Nam, Bongtae Kim, Geun Seog Song, Hyeong‐Seok Lim, Kyun‐Seop Bae
Abstract
Tegoprazan was well tolerated and showed rapid and potent gastric acid suppression. This supports the further development of tegoprazan as a treatment for acid-related disorders.
Related Papers
- → Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor(2001)31 cited
- → Monitoring the growing use of esomeprazole(2019)3 cited
- รปแบบการใชยา Esomeprazole ชนดฉด ในโรงพยาบาลมหาสารคาม(2014)
- Comparative Study on Acid Suppression Effect of Esomeprazole and Other Proton Pump Inhibitors(2012)
- 위식도 역류 질환에 의한 비심인성 흉통 환자에서 에소메프라졸 20 mg 1일 2회 용법의 치료 효과 평가를 위한 공개, 무작위 배정 예비 연구(2020)